NEW ORLEANS -- Jim Furyk was named this week’s AstraZeneca Charity Challenge winner for his first-place standing entering the final round of the Wachovia Championship. The AstraZeneca Charity Challenge, formerly known as the CRESTOR® Charity Challenge, is a season-long competition that recognizes and rewards the tournament leader entering the final round at 35 PGA TOUR events. Through the sponsorship, AstraZeneca will donate $3.5 million this year to designated health care charities and will have donated a three-year total of $9.7 million by the conclusion of the 2006 PGA TOUR season.

For Furyk’s performance, AstraZeneca will donate $100,000 to the Allergy & Asthma Network Mothers of Asthmatics (AANMA) on behalf of Furyk and the Wachovia Championship.

“Everyday AANMA is breaking down barriers and opening doors for patients and their caregivers,” said Nancy Sander, who founded AANMA in 1985 after struggling for years to manage her daughter’s severe allergies and asthma. “We are an informational clearinghouse that gives families practical resources they can use at home and in medical settings. And through education, advocacy and community outreach, we highlight critical issues at the local, state and federal level on behalf of those with allergies and asthma.”

AstraZeneca produces a wide range of products that make significant contributions to treatment options and patient care including CRESTOR, NEXIUM, SEROQUEL, ARIMIDEX, and PULMICORT RESPULES. Through this year’s sponsorship, as part of its commitment to patient health and well being, AstraZeneca will also designate health care related charities across therapeutic areas as recipients at the 35 PGA TOUR events throughout the year.

“AstraZeneca’s partnership with the PGA TOUR is an integral part of our mission of giving back in local communities throughout America,” said Tony Zook, CEO, AstraZeneca U.S. “The AstraZeneca Charity Challenge offers a unique platform for providing important disease awareness, health information and education to make a difference in the lives of patients and consumers everyday.”

The AstraZeneca Charity Challenge is the centerpiece of a multi-year PGA TOUR partnership with AstraZeneca (NYSE:AZN). Last year, AstraZeneca donated $3.5 million through the program. Highlights from the AZCC include:
• Last week, the AstraZeneca Charity Challenge winner at the Zurich Classic of New Orleans was Chris Couch.
• At 14 of the first 15 tournaments of 2006, the AstraZeneca Charity Challenge winner or co-winner went on to win the tournament.
• More than 85 charities have benefited from the program.
• Vijay Singh leads all players with eight AstraZeneca Charity Challenge wins. With some of his charitable “winnings,” Singh donated money to the American Red Cross Hurricane Relief Funds in Florida and New Orleans.

• Other multiple winners have included Tom Lehman, Phil Mickelson, Jim Furyk (four), Stuart Appleby, Chad Campbell, Luke Donald, Sergio Garcia, Rod Pampling and David Toms (three), and the following players who triumphed twice: Bart Bryant, Chris DiMarco, Arron Oberholser, Joe Ogilvie, Kenny Perry, Carl Pettersson, Ted Purdy, Adam Scott and Tiger Woods.

Fans can log on to www.astrazeneca.pgatour.com to read about past AstraZeneca Charity Challenge winners and learn more about AstraZeneca.

Allergy & Asthma Network Mothers of Asthmatics (AANMA)
Allergy & Asthma Network Mothers of Asthmatics (AANMA) is a leading nonprofit organization dedicated to eliminating suffering and death due to asthma, allergies and related conditions through education, advocacy and community outreach.

About AstraZeneca
AstraZeneca is a major international healthcare business engaged in the research, development, manufacture and marketing of prescription pharmaceuticals and the supply of healthcare services. It is one of the world’s leading pharmaceutical companies with healthcare sales of over $21.4 billion and leading positions in sales of gastrointestinal, cardiovascular, respiratory, oncology and neuroscience products. AstraZeneca is listed in the Dow Jones Sustainability Index (Global) as well as the FTSE4Good Index. Worldwide, AstraZeneca has six major research and development sites, four discovery facilities and a clinical research site. In total, AstraZeneca’s R&D organization is comprised of more 11,500 people located in seven countries including Canada, France, India, Japan, Sweden, United Kingdom and the United States.